Aorto Iliac Occlusive Disease Treatment Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Aorto-iliac occlusive disease (AIOD) refers to the narrowing or blockage of the abdominal aorta and iliac arteries, typically caused by atherosclerotic plaque buildup, which restricts blood flow to the lower limbs. Treatment options include endovascular interventions such as angioplasty and stenting as well as surgical bypass procedures, with hybrid approaches increasingly used for complex lesions. The global market for these treatments was valued at approximately USD 2.3 billion in 2025 and is projected to grow at a compound annual growth rate of around 5.0% through 2034.

• •Market size in 2025 is approximately USD 2.3 billion with a forecast CAGR near 5.0%.
• •AIOD most commonly affects patients over 50 and is closely linked to smoking, diabetes, and hypertension.
• •Hospitals represent the primary end-use setting, supported by ambulatory surgical centers for select cases.

The principal growth driver is the rising global prevalence of peripheral arterial disease, fueled by aging populations and the growing burden of diabetes, obesity, and cardiovascular risk factors. Technological advances in endovascular devices, including drug-eluting stents, covered stents, and specialty aorto-iliac devices, are broadening the pool of patients eligible for minimally invasive treatment. Greater clinical awareness, improved diagnostic imaging, and favorable reimbursement frameworks in developed healthcare systems are further supporting procedure volumes.

• •Aging demographics and rising diabetes and atherosclerosis prevalence are expanding the patient base.
• •Device innovation, including drug-coated and covered stents, is improving outcomes and adoption of endovascular repair.
• •Improved imaging and screening are enabling earlier diagnosis and intervention.

The market is segmented by device type into endovascular devices and surgical devices, and by procedure into endovascular procedures, surgical interventions, and hybrid procedures, with endovascular approaches accounting for the dominant and fastest-growing share. By geography, North America leads on the back of high disease prevalence, advanced vascular surgery infrastructure, and strong reimbursement, followed by Europe, while Asia-Pacific is expected to post the highest growth rates due to expanding healthcare access and rising disease awareness.

• •Endovascular procedures represent the largest and fastest-growing procedure segment.
• •Hospitals are the dominant end-use channel, followed by ambulatory surgical centers and specialty clinics.
• •North America holds the leading share, with Asia-Pacific identified as the fastest-growing regional market.

What are the recent trends and outlook?

The most prominent trend is the continued migration from open surgical bypass to less invasive endovascular therapies, supported by ongoing device innovation and shorter recovery times. Drug-coated balloons and drug-eluting stents, along with improved imaging and intravascular guidance tools, are expected to enhance long-term patency and broaden indications to more complex TASC C and D lesions. Looking ahead, the market is projected to reach around USD 3.56 billion by 2034, with sustained mid-single-digit growth driven by demographic trends, technology adoption, and expanding access in emerging markets.

• •Minimally invasive endovascular procedures are steadily replacing open surgical bypass as the preferred first-line approach.
• •Drug-coated balloons and drug-eluting stents are expected to drive improved long-term outcomes.
• •The market is forecast to reach approximately USD 3.56 billion by 2034, supported by expansion in Asia-Pacific and other emerging regions.